Selective inhibition of human cytochrome P4502C8 by montelukast.
The leukotriene receptor antagonist montelukast was examined for its inhibition of the human drug-metabolizing enzyme cytochrome P4502C8 (CYP2C8). Montelukast was demonstrated to be a potent inhibitor of CYP2C8-catalyzed amodiaquine N-deethylase, rosiglitazone N-demethylase, and paclitaxel 6alpha-hydroxylase in human liver microsomes. Inhibition was also observed when the reaction was catalyzed by recombinant heterologously expressed CYP2C8. The mechanism of inhibition was competitive, with K(i) values ranging from 0.0092 to 0.15 microM. Inhibition potency was highly dependent on the microsomal protein concentration. Increasing the microsomal protein concentration by 80-fold yielded a 100-fold decrease in inhibition potency. Preincubation of montelukast with human liver microsomes and NADPH did not alter the inhibition potency, suggesting that montelukast is not a mechanism-based inactivator. Montelukast was a selective inhibitor for human CYP2C8; inhibition of other human cytochrome P450 enzymes was substantially less. These in vitro data support the use of montelukast as a selective CYP2C8 inhibitor that could be used to determine the contribution of this enzyme to drug metabolism reactions. These data also raise the possibility that montelukast could have an effect on the metabolic clearance of drugs possessing CYP2C8-catalyzed metabolism as a major clearance pathway, thereby eliciting pharmacokinetic drug-drug interactions.
Walsky
Robert L
RL
Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA.
Obach
R Scott
RS
Gaman
Emily A
EA
Gleeson
Jean-Paul R
JP
Proctor
William R
WR
D000085:Acetates / Q000494:pharmacology*; D000655:Amodiaquine / Q000494:pharmacology; D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003521:Cyclopropanes; D065727:Cytochrome P-450 CYP2C8; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D020024:Leukotriene Antagonists / Q000494:pharmacology*; D008862:Microsomes, Liver / Q000201:enzymology; D017239:Paclitaxel / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000378:metabolism; D000077154:Rosiglitazone; D013440:Sulfides; D045162:Thiazolidinediones / Q000494:pharmacology
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D004791:Enzyme Inhibitors; D020024:Leukotriene Antagonists; D011804:Quinolines; D011994:Recombinant Proteins; D013440:Sulfides; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000655:Amodiaquine; D001189:Aryl Hydrocarbon Hydroxylases; C450259:CYP2C8 protein, human; D065727:Cytochrome P-450 CYP2C8; C093875:montelukast; D017239:Paclitaxel